FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221120273> ?p ?o ?g. }

• W4221120273 endingPage "03" @default.
• W4221120273 startingPage "P1" @default.
• W4221120273 abstract "Abstract Background: Despite the advances by targeted therapies, particularly in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC), chemotherapy remains a mainstay of the treatment in all breast cancer subtypes. Response probabilities to chemotherapy seem to decrease with increasing lines of treatment, but little is known about the response dependency on the previous therapy line. Here, we present data from the MBC registry of the Austrian Study Group for Medical Tumor Therapy (AGMT-MBC-Registry). Methods: The AGMT-MBC-Registry is an ongoing multicenter registry for MBC patients in Austria. Patients with available hormone receptor and negative HER2 status, at least two consecutive lines of chemotherapy and sufficient progression-free survival (PFS) data were included in this analysis. Multivariable adjusted hazard ratios (HR) for PFS were estimated by Cox regression models and included the following parameters: age, HR status, disease-free survival (de novo metastatic or ≥ 24 months vs. &lt; 24 months), visceral disease, number of involved metastatic sites at diagnosis of MBC, chemotherapy treatment line, and response in previous treatment line. Response was defined as PFS &gt; 4 month and non-response as a PFS ≤ 4 month. Cox model was extended as proposed by Andersen and Gill due to possibility of multiple events per patient and thereby resulting dependencies (Sousa-Ferreira & Abreu, 2019). Results: As of 15/04/2021, 2024 patients were included in the registry. Out of them, 405 patients (20.0%) had documented HER2 negative disease with at least two lines of consecutive chemotherapy. Median PFS for first-, second-, third-, and forth-line chemotherapy were 6.0 months (95% CI 5.5-6.5), 3.7 months (95% CI 3.1-4.3), 2.9 months (95% CI 2.5-3.2), and 2.8 months (95% CI 2.6-3.2), respectively. Median overall survival was 31.8 months (95% CI 27.2-34.8). Median number of chemotherapy lines was 3 (range 2-8). The most commonly used cytotoxic agents were paclitaxel and capecitabine in first- and second-line, and eribulin in third-, and fourth-line chemotherapy. Combinations of more than one cytotoxic drug were given in 36%, 29%, 28% in first-, second-, and third/fourth-line. Patients who did not respond to the previous therapy line, had a response in 43% (95% CI 33-53), 34% (95% CI 25-43), and 30% (95% CI 21-39) to second-, third-, and fourth-line. In those patients, investigator assessed overall response rate (partial remission or complete remission) was 27% (95% CI 13-40), 23% (95% CI 9-37), and 33% (95% CI 16-51), respectively. A response to third-line chemotherapy in patients who did not respond to first- and second-line therapy, was seen in 16.7% of patients. Ratios between PFS of interest and PFS of the previous treatment line were 0.63 (95% CI 0.55-0.68), 0.57 (95% CI 0.41-0.62), and 0.76 (95% CI 0.58-0.9) in second-, third-, and forth-line therapy. In multivariable analysis, responses in second- to fourth-line therapy were statistically significant associated with disease-free survival (HR 0.75, P=0.022), and treatment line (HR 1.17 per increasing treatment line, P=0.004), but not for the response to the previous treatment line (HR 0.85, P=0.068). Conclusion: A continuously decreasing PFS for cytotoxic drugs from treatment line to treatment line was confirmed in our analysis. However, in multivariable analysis, response, defined as PFS &gt; 4 months, was not statistically associated with response to the previous treatment line. Therefore, a lack of response to first, second-, - or third-line chemotherapy should not trigger discontinuation of anticancer therapy in case of further available treatment options. Citation Format: Gabriel Rinnerthaler, Simon P Gampenrieder, Christoph Tinchon, Andreas Petzer Petzer, Marija Balic, Heibl Sonja, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christophe Hager, Michael Hubalek, Michael Knauer, Christian F Singer, Richard Greil. Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-16-03." @default.
• W4221120273 created "2022-04-03" @default.
• W4221120273 creator A5005105234 @default.
• W4221120273 creator A5007988543 @default.
• W4221120273 creator A5015052494 @default.
• W4221120273 creator A5017213717 @default.
• W4221120273 creator A5018155083 @default.
• W4221120273 creator A5019447310 @default.
• W4221120273 creator A5036026407 @default.
• W4221120273 creator A5039994927 @default.
• W4221120273 creator A5045257898 @default.
• W4221120273 creator A5049254392 @default.
• W4221120273 creator A5053620668 @default.
• W4221120273 creator A5066677441 @default.
• W4221120273 creator A5068295312 @default.
• W4221120273 creator A5072120604 @default.
• W4221120273 creator A5082631402 @default.
• W4221120273 creator A5083154064 @default.
• W4221120273 creator A5087125819 @default.
• W4221120273 date "2022-02-15" @default.
• W4221120273 modified "2023-10-16" @default.
• W4221120273 title "Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry" @default.
• W4221120273 doi "https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03" @default.
• W4221120273 hasPublicationYear "2022" @default.
• W4221120273 type Work @default.
• W4221120273 citedByCount "0" @default.
• W4221120273 crossrefType "journal-article" @default.
• W4221120273 hasAuthorship W4221120273A5005105234 @default.
• W4221120273 hasAuthorship W4221120273A5007988543 @default.
• W4221120273 hasAuthorship W4221120273A5015052494 @default.
• W4221120273 hasAuthorship W4221120273A5017213717 @default.
• W4221120273 hasAuthorship W4221120273A5018155083 @default.
• W4221120273 hasAuthorship W4221120273A5019447310 @default.
• W4221120273 hasAuthorship W4221120273A5036026407 @default.
• W4221120273 hasAuthorship W4221120273A5039994927 @default.
• W4221120273 hasAuthorship W4221120273A5045257898 @default.
• W4221120273 hasAuthorship W4221120273A5049254392 @default.
• W4221120273 hasAuthorship W4221120273A5053620668 @default.
• W4221120273 hasAuthorship W4221120273A5066677441 @default.
• W4221120273 hasAuthorship W4221120273A5068295312 @default.
• W4221120273 hasAuthorship W4221120273A5072120604 @default.
• W4221120273 hasAuthorship W4221120273A5082631402 @default.
• W4221120273 hasAuthorship W4221120273A5083154064 @default.
• W4221120273 hasAuthorship W4221120273A5087125819 @default.
• W4221120273 hasConcept C121608353 @default.
• W4221120273 hasConcept C126322002 @default.
• W4221120273 hasConcept C143998085 @default.
• W4221120273 hasConcept C207103383 @default.
• W4221120273 hasConcept C2775930923 @default.
• W4221120273 hasConcept C2776694085 @default.
• W4221120273 hasConcept C2778527826 @default.
• W4221120273 hasConcept C2780739268 @default.
• W4221120273 hasConcept C44249647 @default.
• W4221120273 hasConcept C50382708 @default.
• W4221120273 hasConcept C530470458 @default.
• W4221120273 hasConcept C71924100 @default.
• W4221120273 hasConceptScore W4221120273C121608353 @default.
• W4221120273 hasConceptScore W4221120273C126322002 @default.
• W4221120273 hasConceptScore W4221120273C143998085 @default.
• W4221120273 hasConceptScore W4221120273C207103383 @default.
• W4221120273 hasConceptScore W4221120273C2775930923 @default.
• W4221120273 hasConceptScore W4221120273C2776694085 @default.
• W4221120273 hasConceptScore W4221120273C2778527826 @default.
• W4221120273 hasConceptScore W4221120273C2780739268 @default.
• W4221120273 hasConceptScore W4221120273C44249647 @default.
• W4221120273 hasConceptScore W4221120273C50382708 @default.
• W4221120273 hasConceptScore W4221120273C530470458 @default.
• W4221120273 hasConceptScore W4221120273C71924100 @default.
• W4221120273 hasIssue "4_Supplement" @default.
• W4221120273 hasLocation W42211202731 @default.
• W4221120273 hasOpenAccess W4221120273 @default.
• W4221120273 hasPrimaryLocation W42211202731 @default.
• W4221120273 hasRelatedWork W2070780645 @default.
• W4221120273 hasRelatedWork W2092771806 @default.
• W4221120273 hasRelatedWork W2098203737 @default.
• W4221120273 hasRelatedWork W2139647583 @default.
• W4221120273 hasRelatedWork W2622612196 @default.
• W4221120273 hasRelatedWork W2782589310 @default.
• W4221120273 hasRelatedWork W3163505858 @default.
• W4221120273 hasRelatedWork W377899687 @default.
• W4221120273 hasRelatedWork W4224323651 @default.
• W4221120273 hasRelatedWork W4312115202 @default.
• W4221120273 hasVolume "82" @default.
• W4221120273 isParatext "false" @default.
• W4221120273 isRetracted "false" @default.
• W4221120273 workType "article" @default.